Trial · NCT02008721
Results by group98
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 98
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. | EGCG as Putative Neuroprotective Agent | 5.66 | Standard Deviation 1.01 | score on a scale | |
| Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. | Placebo | 6.60 | Standard Deviation 0.99 | score on a scale | |
| Possible Symptomatic Effects of EGCG vs. Placebo Measured by the Change in the UMSARS - ME in the Wash-out Phase (From V6-V7) | EGCG as Putative Neuroprotective Agent | 0.68 | Standard Deviation 0.60 | score on a scale | |
| Possible Symptomatic Effects of EGCG vs. Placebo Measured by the Change in the UMSARS - ME in the Wash-out Phase (From V6-V7) | Placebo | 0.49 | Standard Deviation 0.58 | score on a scale | |
| Change in the UMSARS Total Score From V1 to V7 | EGCG as Putative Neuroprotective Agent | 10.33 | Standard Deviation 1.73 | score on a scale | |
| Change in the UMSARS Total Score From V1 to V7 | Placebo | 10.35 | Standard Deviation 1.71 | score on a scale | |
| Possible Symptomatic Effects of EGCG vs. Placebo Measured by the UMSARS Total Score From V6 to V7 (During the Washout Phase) | EGCG as Putative Neuroprotective Agent | 0.70 | Standard Deviation 0.91 | score on a scale | |
| Possible Symptomatic Effects of EGCG vs. Placebo Measured by the UMSARS Total Score From V6 to V7 (During the Washout Phase) | Placebo | -0.29 | Standard Deviation 0.88 | score on a scale | |
| Percentage of Striatal Volume Loss in MRI (3D MP-RAGE MRI Volumetry, 3D FLAIR) From Baseline to V7 as Effect of Treatment (Epigallocatechin Gallate vs Placebo) | EGCG as Putative Neuroprotective Agent | -0.029 | Standard Deviation 0.027 | % of volume loss | |
| Percentage of Striatal Volume Loss in MRI (3D MP-RAGE MRI Volumetry, 3D FLAIR) From Baseline to V7 as Effect of Treatment (Epigallocatechin Gallate vs Placebo) | Placebo | -0.064 | Standard Deviation 0.026 | % of volume loss | |
| Clinical Safety and Tolerability of EGCG Measured by Death Rates | EGCG as Putative Neuroprotective Agent | 4 | Participants | ||
| Clinical Safety and Tolerability of EGCG Measured by Death Rates | Placebo | 2 | Participants | ||
| Effect of Treatment (Epigallocatechin Gallate vs Placebo) on Safety and Tolerability: Discontinuation Rates Because of Hepatotoxicity | EGCG as Putative Neuroprotective Agent | 2 | Participants | ||
| Effect of Treatment (Epigallocatechin Gallate vs Placebo) on Safety and Tolerability: Discontinuation Rates Because of Hepatotoxicity | Placebo | 0 | Participants | ||
| Number of Participants Achieving Each Clinical Global Impression of Severity (CGI-S): Illness Level at Visit 1 | EGCG as Putative Neuroprotective Agent | Severity of illness=1 | 2 | participants | |
| Number of Participants Achieving Each Clinical Global Impression of Severity (CGI-S): Illness Level at Visit 1 | Placebo | Severity of illness=1 | 1 | participants | |
| Number of Participants Achieving Each Clinical Global Impression of Severity (CGI-S): Illness Level at Visit 1 | EGCG as Putative Neuroprotective Agent | severity of illness =2 | 1 | participants | |
| Number of Participants Achieving Each Clinical Global Impression of Severity (CGI-S): Illness Level at Visit 1 | Placebo | severity of illness =2 | 0 | participants | |
| Number of Participants Achieving Each Clinical Global Impression of Severity (CGI-S): Illness Level at Visit 1 | EGCG as Putative Neuroprotective Agent | severity of illness=3 | 8 | participants | |
| Number of Participants Achieving Each Clinical Global Impression of Severity (CGI-S): Illness Level at Visit 1 | Placebo | severity of illness=3 | 6 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02008721/results